Sanofi (NASDAQ:SNY) Stake Lifted by West Family Investments Inc.

West Family Investments Inc. boosted its holdings in Sanofi (NASDAQ:SNY) by 50.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,219 shares of the company’s stock after acquiring an additional 2,079 shares during the quarter. West Family Investments Inc.’s holdings in Sanofi were worth $358,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. POM Investment Strategies LLC purchased a new stake in shares of Sanofi in the 2nd quarter valued at approximately $25,000. Northwest Investment Counselors LLC acquired a new position in Sanofi during the third quarter worth $29,000. Concord Wealth Partners raised its stake in shares of Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares in the last quarter. Arrow Financial Corp bought a new position in shares of Sanofi in the second quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the period. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Shares of SNY opened at $48.00 on Wednesday. The firm has a market cap of $121.82 billion, a P/E ratio of 24.49, a PEG ratio of 1.22 and a beta of 0.61. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The firm’s 50 day moving average price is $54.25 and its two-hundred day moving average price is $52.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the prior year, the company posted $2.55 earnings per share. Sanofi’s revenue was up 12.3% on a year-over-year basis. On average, analysts forecast that Sanofi will post 4.29 EPS for the current fiscal year.

Analyst Ratings Changes

SNY has been the topic of several recent analyst reports. Argus lifted their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.